20 categories
Evidence
Published evidence, read closely. Trial digests, journal club, meta-analyses, preprints, and structured critique.
148 topics · page 1 of 5
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Journal club: LEADER as the historical anchor
Journal club: LEADER as the historical anchor Writing it up because I had to work it out twice and would rather nobody else did. Comparing STEP 1 ( N Engl J Med , 2021) with SURMOUNT-4 ( JAMA , 2024) and…
|
+103 | 110 | 8.1k | 2h |
|
About the Preprints category
Unrefereed work, clearly labelled as such, with the usual caveats stated once and taken seriously. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded…
|
+3 | 7 | 14k | 3mo |
|
Citing a preprint in a maintained document: our rule and its reasoning
On the subject in the title: Citing a preprint in a maintained document: our rule and its reasoning Working notes rather than a conclusion. I have seen SELECT ( N Engl J Med , 2023) cited in support of a…
|
2 | 467 | 4mo | |
|
Critiquing an observational claim about a class effect — one year on
Critiquing an observational claim about a class effect — one year on — setting out what I have, and where I think it stops being reliable. I have seen LEADER ( N Engl J Med , 2016) cited in support of a claim…
|
+5 | 9 | 3.2k | 8mo |
|
About the Trials category
Individual randomised trials: design, population, endpoints, results, and limitations. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its…
|
+6 | 10 | 27k | 12mo |
|
About the Meta-analyses category
Pooled estimates, heterogeneity, publication bias, and when pooling was a mistake. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its author…
|
4 | 15k | 13mo | |
|
Comparators chosen for regulatory reasons rather than clinical ones
On the subject in the title: Comparators chosen for regulatory reasons rather than clinical ones Working notes rather than a conclusion. Session topic: SURMOUNT-1 ( N Engl J Med , 2022). Please read it before…
|
2 | 27k | 14mo | |
|
About the Study critique category
Structured criticism of a specific published study. Criticise the method, not the author. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its…
|
4 | 114 | 16mo | |
|
About the Journal club category
Our recurring session. One named paper per topic, methods first, conclusions last. Everyone reads before posting. This post is a community wiki: any member at trust level 3 or above can edit it, and every…
|
+2 | 6 | 12k | 16mo |
|
Second pass at: When a network meta-analysis is defensible and when it is not
Posting this under the heading it deserves: Second pass at: When a network meta-analysis is defensible and when it is not Everything below is what sits behind that. Comparing STEP 8 ( JAMA , 2022) with LEADER…
|
2 | 2.8k | 21mo | |
|
Journal club: indirect comparison between two programmes, defended and attacked
Journal club: indirect comparison between two programmes, defended and attacked Writing it up because I had to work it out twice and would rather nobody else did. Comparing SUSTAIN 6 ( N Engl J Med , 2016)…
|
+122 | 131 | 5.2k | just now |
|
When a network meta-analysis is defensible and when it is not
When a network meta-analysis is defensible and when it is not I have a specific reason for asking rather than idle curiosity, and the context is below. Comparing SUSTAIN 6 ( N Engl J Med , 2016) with LEADER (…
|
2 | 27k | 4h | |
|
Journal club: STEP 1 and the treatment-policy estimand
Journal club: STEP 1 and the treatment-policy estimand Writing it up because I had to work it out twice and would rather nobody else did. Comparing SUSTAIN 6 ( N Engl J Med , 2016) with STEP 8 ( JAMA , 2022)…
|
3 | 11k | 9h | |
|
What a statistical analysis plan adds that the paper does not
What a statistical analysis plan adds that the paper does not — that is the question, and I have not found it answered plainly anywhere I have looked. I have seen SCALE ( N Engl J Med , 2015) cited in support…
|
2 | 6.6k | 10h | |
|
Second pass at: Reading a trial's population section before its results
Second pass at: Reading a trial's population section before its results Writing it up because I had to work it out twice and would rather nobody else did. I have seen STEP 1 ( N Engl J Med , 2021) cited in…
|
4 | 9.5k | 10h | |
|
Primary endpoint hierarchies and why order matters — one year on
On the subject in the title: Primary endpoint hierarchies and why order matters — one year on Working notes rather than a conclusion. Comparing SELECT ( N Engl J Med , 2023) with SURPASS-2 ( N Engl J Med ,…
|
+56 | 61 | 37k | 11h |
|
Composite endpoints and the component doing the work
Composite endpoints and the component doing the work Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURPASS-4 ( Lancet , 2021) cited in support of a claim I do…
|
+3 | 7 | 33k | 13h |
|
Journal club: STEP 8 and the fairness of the comparator dose — a second dataset
Posting this under the heading it deserves: Journal club: STEP 8 and the fairness of the comparator dose — a second dataset Everything below is what sits behind that. Session topic: SURPASS-2 ( N Engl J Med ,…
|
+18 | 22 | 656 | 13h |
|
Journal club: semaglutide in MASH, and surrogate endpoints
Posting this under the heading it deserves: Journal club: semaglutide in MASH, and surrogate endpoints Everything below is what sits behind that. Comparing SCALE ( N Engl J Med , 2015) with SURMOUNT-2 (…
|
+24 | 28 | 17k | 15h |
|
Journal club: STEP 1 and the treatment-policy estimand — does this still hold?
Asking directly, because I could not find a straight answer: Journal club: STEP 1 and the treatment-policy estimand — does this still hold? Comparing STEP 2 ( Lancet , 2021) with SURPASS-2 ( N Engl J Med ,…
|
+70 | 76 | 4.8k | 15h |
|
A structured critique template this community uses — a second dataset
On the subject in the title: A structured critique template this community uses — a second dataset Working notes rather than a conclusion. Session topic: SELECT ( N Engl J Med , 2023). Please read it before…
|
+47 | 51 | 16k | 15h |
|
A critique that turned out to be unfair, retracted by its author
Posting this under the heading it deserves: A critique that turned out to be unfair, retracted by its author Everything below is what sits behind that. Session topic: SURMOUNT-4 ( JAMA , 2024). Please read it…
|
+34 | 38 | 20k | 17h |
|
Coming back to: A structured critique template this community uses
Posting this under the heading it deserves: A structured critique template this community uses Everything below is what sits behind that. Comparing STEP 8 ( JAMA , 2022) with SURMOUNT-1 ( N Engl J Med , 2022)…
|
+63 | 69 | 17k | 18h |
|
Revisiting: What pooling buys you and what it destroys
On the subject in the title: Revisiting: What pooling buys you and what it destroys Working notes rather than a conclusion. Session topic: PIONEER 6 ( N Engl J Med , 2019). Please read it before posting; the…
|
+97 | 107 | 4k | 19h |
|
Journal club: the CagriSema phase 2 combination paper
On the subject in the title: Journal club: the CagriSema phase 2 combination paper Working notes rather than a conclusion. I have seen SURMOUNT-1 ( N Engl J Med , 2022) cited in support of a claim I do not…
|
2 | 329 | 21h | |
|
Immortal time bias in a claims-database study — one year on
Posting this under the heading it deserves: Immortal time bias in a claims-database study — one year on Everything below is what sits behind that. Comparing SURPASS-2 ( N Engl J Med , 2021) with SURMOUNT-1 (…
|
+41 | 46 | 3.7k | 22h |
|
Journal club: what we got wrong in an earlier session
On the subject in the title: Journal club: what we got wrong in an earlier session Working notes rather than a conclusion. Session topic: SURMOUNT-1 ( N Engl J Med , 2022). Please read it before posting; the…
|
+114 | 125 | 2.5k | 23h |
|
Risk-of-bias tools and the judgement they conceal — does this still hold?
Risk-of-bias tools and the judgement they conceal — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Comparing SURPASS-2 ( N Engl J Med , 2021)…
|
+26 | 30 | 5.8k | 23h |
|
Pooling trials with different estimands
On the subject in the title: Pooling trials with different estimands Working notes rather than a conclusion. Comparing SELECT ( N Engl J Med , 2023) with SURMOUNT-1 ( N Engl J Med , 2022) and finding the…
|
+120 | 132 | 2.3k | 1d |
|
A structured critique template this community uses
A structured critique template this community uses — setting out what I have, and where I think it stops being reliable. Comparing SURMOUNT-2 ( Lancet , 2023) with SURPASS-4 ( Lancet , 2021) and finding the…
|
2 | 18k | 1d |